ClassID:

20331

A61K31/417 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole 1,3-Diazoles Imidazole-alkylamines, e.g. histamine, phentolamine

Recent Application in this class:
#1
20260132123
2026-05-14

ABAD INHIBITOR COMPOUNDS

#2
20260109699
2026-04-23

AZOLE DERIVATIVES AS SHP2 INHIBITORS

#3
20260092039
2026-04-02

DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

#4
20260076944
2026-03-19

COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH

#5
20260062388
2026-03-05

POLYMORPHIC FORM OF NEPICASTAT ACID ADDITION SALT, PREPARATION METHOD THEREFOR AND USE THEREOF

#6
20260060960
2026-03-05

GAMMA-SECRETASE INHIBITORS FOR USE IN THE TREATMENT OF INHERITED EPIDERMOLYSIS BULLOSA

#7
20260053796
2026-02-26

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

#8
20260034099
2026-02-05

CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS

#9
20260027084
2026-01-29

TREATMENT OF MULTIPLE MYELOMA

#10
20260015316
2026-01-15

COMPOSITIONS AND METHODS FOR TREATING CANCER

#11
20250352650
2025-11-20

TOPICAL COMPOSITION

#12
20250352516
2025-11-20

ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBROVASCULAR DISEASE

#13
20250340510
2025-11-06

Substituted Phenylbenzenesulfonamide Derivatives and Uses Thereof

#14
20250332159
2025-10-30

REACTIVE OXYGEN SPECIES MODULATION THROUGH BINDING OF LIGANDS AT THE NQ-BINDING SITE OF THE RESPIRATORY COMPLEX III

#15
20250312347
2025-10-09

THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS

#16
20250262152
2025-08-21

DEVICES, SYSTEMS, KITS, AND METHODS FOR DRUG DELIVERY TO THE SPINAL CORD

#17
20250262149
2025-08-21

AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF

#18
20250248931
2025-08-07

AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF

#19
20250248930
2025-08-07

AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF

#20
20250228995
2025-07-17

BIOACTIVE POLYMERIC DRESSING FOR ACCELERATED WOUND CLOSURE

#21
20250162995
2025-05-22

PHENTOLAMINE MESYLATE AND THERAPEUTIC USES THEREOF

#22
20250161275
2025-05-22

METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS

#23
20250161274
2025-05-22

METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS

#24
20250134870
2025-05-01

PATHWAY MODULATOR, PHARMACEUTICAL COMPOSITION HAVING SAME, USE THEREOF, AND THERAPEUTIC METHOD USING SAME

#25
20250064830
2025-02-27

TRANSDERMAL TREATMENT FOR ERECTILE DYSFUNCTION

#26
20250057814
2025-02-20

ENDODONTIC BIOFILM-ERADICATION TECHNIQUE UTILIZING A DUAL-SYSTEM INTRACANAL MEDICATION

#27
20250025446
2025-01-23

TREATMENTS WITH NIROGACESTAT

#28
20250000792
2025-01-02

DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS

#29
20240425460
2024-12-26

CRYSTAL FORM OF NIROGACESTAT DIHYDROBROMIDE, AND PREPARATION METHOD THEREFOR, AND USE THEREOF

#30
20240408067
2024-12-12

SOLID STATE FORMS OF NIROGACESTAT SALTS

#31
20240398762
2024-12-05

PHARMACEUTICAL COMPOSITION WITH ANALGESIC AND/OR ANTIPRURITIC FUNCTIONS AND APPLICATION THEREOF

#32
20240325321
2024-10-03

COMPOSITIONS AND METHODS FOR INHIBITING PLpro PROTEASE ACTIVITY AND FOR PREVENTING AND TREATING SARS-CoV-2 INFECTION

#33
20240316007
2024-09-26

COMPOSITIONS AND TREATMENTS WITH NIROGACESTAT

#34
20240299680
2024-09-12

MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODS

#35
20240299299
2024-09-12

COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES

#36
20240285584
2024-08-29

AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDERECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS

#37
20240285519
2024-08-29

AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF

#38
20240277668
2024-08-22

HISTAMINE RECEPTOR AGONISTS FOR CANCER THERAPY IN CANCER PATIENTS UNRESPONSIVE TO CANCER IMMUNOTHERAPY AND WITH ELEVATED MYELOID DERIVED SUPPRESSOR CELLS

#39
20240270701
2024-08-15

BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME

#40
20240269123
2024-08-15

MUSCLE REGENERATION PROMOTER

#41
20240261459
2024-08-08

Bioactive polymeric dressing for accelerated wound closure

#42
20240245648
2024-07-25

Treatments with nirogacestat

#43
20240216334
2024-07-04

METHODS AND COMPOSITIONS FOR TREATING MYDRIASIS, GLAUCOMA, AND OTHER OCULARCONDITIONS

#44
20240197694
2024-06-20

MODIFIED PROTEINS AND PROTEIN BINDERS

#45
20240189283
2024-06-13

L-ERGOTHIONEINE-CONTAINING COMPOSITION

#46
20240189282
2024-06-13

Treatments with nirogacestat

#47
20240180874
2024-06-06

IMPROVED TREATMENT OF OVARIAN CANCER WITH NIROGACESTAT

#48
20240166758
2024-05-23

COMBINATION THERAPIES FOR TREATMENT OF BCMA-RELATED CANCERS AND AUTOIMMUNE DISORDERS

#49
20240156784
2024-05-16

Treatments with nirogacestat

#50
20240148695
2024-05-09

Treatments with nirogacestat

#51
20240148646
2024-05-09

Dry powder formulations of epinephrine and associated methods

#52
20240131023
2024-04-25

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

#53
20240075012
2024-03-07

COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION

#54
20240066007
2024-02-29

Treatments with nirogacestat

#55
20240058307
2024-02-22

CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS

#56
20240050412
2024-02-15

METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISUAL PERFORMANCE

#57
20240042259
2024-02-08

NERVE AGENT DECONTAMINATING AGENTS

#58
20240009207
2024-01-11

CANNABIDIOL (CBD) BASED COMPOSITION AND METHOD FOR TREATING PAIN

#59
20240002935
2024-01-04

GENETIC METHOD FOR DIAGNOSIS AND TREATMENT OF PRE AND POST CORONAVIRUS INFECTIONS

#60
20230414571
2023-12-28

APPLICATION OF SMALL-MOLECULE COMPOUND IN PREPARATION OF ANTITUMOR DRUG

#61
20230405124
2023-12-21

GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF IMMUNE SYSTEM DYSFUNCTION

#62
20230390215
2023-12-07

SYSTEMS, DEVICES, AND FORMULATIONS FOR TIME-PHASED HISTAMINE DELIVERY

#63
20230381146
2023-11-30

SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF

#64
20230372534
2023-11-23

CONJUGATES OF ACTIVE PHARMACEUTICAL INGREDIENTS

#65
20230338304
2023-10-26

USE OF CANNABINOIDS IN TREATING ANTI-DEPRESSANT-INDUCED FEMALE SEXUAL DYSFUNCTION

#66
20230321017
2023-10-12

ACIDIC CANNABINOIDS AND USES THEREOF FOR ENHANCING FEMALE SEXUAL FUNCTION OR TREATING FEMALE SEXUAL DISORDERS

#67
20230310379
2023-10-05

Chlorinated tetralin compounds and pharmaceutical compositions

#68
20230301968
2023-09-28

PHARMACEUTICAL COMPOSITIONS COMPRISING FLUBENDAZOLE

#69
20230277549
2023-09-07

NOTCH SIGNALING INHIBITORS FOR TREATING OBESITY AND METABOLIC DISORDERS

#70
20230250065
2023-08-10

Chlorinated tetralin compounds and pharmaceutical compositions

#71
20230241030
2023-08-03

MACROGOL 15 HYDROXYSTEARATE FORMULATIONS

#72
20230241029
2023-08-03

METHODS OF REDUCING POST-SURGICAL METASTASIS

#73
20230240983
2023-08-03

DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS

#74
20230233460
2023-07-27

Dry powder formulations of epinephrine and associated methods

#75
20230218601
2023-07-13

Analgesic formulations and methods for reduced postoperative nausea and vomiting and enhanced postoperative pain relief

#76
20230191047
2023-06-22

Medical counter measures including dry powder formulations and associated methods

#77
20230133044
2023-05-04

THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS

#78
20230121797
2023-04-20

A COMBINATION OF FLAVONOIDS AND SPHINGOSINE 1 PHOSPHATE LYASE INHIBITORS FOR THE TREATMENT OF LUNG INFLAMMATION

#79
20230121547
2023-04-20

A COMBINATION THERAPY WITH NIROGACESTAT AND A BCMA-DIRECTED THERAPY AND USES THEREOF

#80
20230118152
2023-04-20

FORMS OF 5-({[2-AMINO-3-(4-CARBAMOYL-2,6-DIMETHYL-PHENYL)-PROPIONYL]-[1-(4-PHENYL-1H-IMIDAZOL-2-YL)-ETHYL]-AMINO}-METHYL)-2-METHOXY-BENZOIC ACID

#81
20230116770
2023-04-13

Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof

#82
20230112444
2023-04-13

COMBINATION THERAPIES OF CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN AND GAMMA SECRETASE INHIBITORS

#83
20230091097
2023-03-23

CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS

#84
20230090557
2023-03-23

Chlorinated tetralin compounds and pharmaceutical compositions

#85
20230088856
2023-03-23

CHLORINATED TETRALIN COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS

#86
20230079407
2023-03-16

ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF

#87
20230062844
2023-03-02

Composition and methods for the treatment of myopia

#88
20230051178
2023-02-16

Self-healing organic crystals

#89
20230040217
2023-02-09

Methods and compositions for treatment of mydriasis

#90
20230032637
2023-02-02

Methods and compositions for treatment of mydriasis

#91
20230022570
2023-01-26

TOPICAL COMPOSITION

#92
20220401381
2022-12-22

PERIPHERALLY ACTING CANNABIDIOL (CBD)-CONTAINING COMPOUNDS AND USES THEREOF FOR ENHANCING FEMALE SEXUAL FUNCTION OR TREATING FEMALE SEXUAL DISORDERS

#93
20220395457
2022-12-15

Dry powder formulations of epinephrine and associated methods

#94
20220387549
2022-12-08

GLP-1 COMPOUND

#95
20220332821
2022-10-20

DOSING REGIMEN AND COMBINATION THERAPIES FOR MULTISPECIFIC ANTIBODIES TARGETING B-CELL MATURATION ANTIGEN

#96
20220280514
2022-09-08

METHODS OF TREATING BILE ACID DIARRHEA

#97
20220226287
2022-07-21

Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders

#98
20220218668
2022-07-14

COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION

#99
20220202778
2022-06-30

ISOTOPE-ENRICHED 3-AMINO-1-PROPANESULFONIC ACID DERIVATIVES FOR THE TREATMENT OF CEREBROVASCULAR DISEASE

#100
20220202777
2022-06-30

AMIDE DERIVATIVES OF N-UREA SUBSTITUTED AMINO ACIDS AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS

#101
20220175734
2022-06-09

USING PARASYMPATHOMIMETIC DRUGS ALONE OR, IN COMBINATION WITH ONE OR MORE ALPHA AGONISTS IN PSEUDOPHAKIC PATIENTS, TO CREATE MULTI-FOCALITY

#102
20220175668
2022-06-09

Aqueous ophthalmic solutions of phentolamine and medical uses thereof

#103
20220168417
2022-06-02

COMBINATION THERAPY WITH AN ANTI BCMA ANTIBODY AND A GAMMA SECRETASE INHIBITOR

#104
20220125802
2022-04-28

Transdermal treatment for erectile dysfunction

#105
20220088010
2022-03-24

Co-Administration of inhibitors to produce insulin producing gut cells

#106
20220073452
2022-03-10

Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

#107
20220062439
2022-03-03

LOCALIZED ADMINISTRATION OF RNA MOLECULES FOR THERAPY

#108
20220000880
2022-01-06

METHOD AND COMPOSITION EMBODIMENTS FOR TREATING ACUTE MYELOID LEUKEMIA

#109
20210393572
2021-12-23

PHARMACEUTICALLY ACTIVE CANNABIS-BASED COMPOSITIONS AND METHODS OF USE FOR TREATING GASTROINTESTINAL CONDITIONS

#110
20210346350
2021-11-11

Methods and compositions for treatment of glaucoma and related conditions

#111
20210346349
2021-11-11

METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS

#112
20210338638
2021-11-04

Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance

#113
20210292417
2021-09-23

HISTAMINE DIHYDROCHLORIDE COMBINATIONS AND USES THEREOF

#114
20210290633
2021-09-23

COMBINATION FOR TREATING CANCER

#115
20210283069
2021-09-16

Use of cannabinoids in treating anti-depressant-induced female sexual dysfunction

#116
20210275498
2021-09-09

IMIDAZOLYL ETHANAMIDE PENTANDIOIC ACID FOR USE IN THERAPY OF SYMPTOMS RELATED TO EXPOSURE TO LETHAL RADIATION

#117
20210275497
2021-09-09

MACROGOL 15 HYDROXYSTEARATE FORMULATIONS

#118
20210269399
2021-09-02

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#119
20210251964
2021-08-19

POLYMORPHS OF 5-({[2-AMINO-3-(4-CARBAMOYL-2,6-DIMETHYL-PHENYL)-PROPIONYL]-[1-(4-PHENYL-1H-IMIDAZOL-2-YL)-ETHYL]-AMINO}-METHYL)-2-METHOXY-BENZOIC ACID

#120
20210196710
2021-07-01

Compounds and methods for the targeted degradation of androgen receptor

#121
20210196681
2021-07-01

SELECTIVE PRESENILIN-2 GAMMA-SECRETASE INHIBITORS

#122
20210187072
2021-06-24

METHODS AND COMPOSITIONS FOR REDUCING RISK OF RELAPSE AND PROLONGING SURVIVAL IN ACUTE MYELOID LEUKEMIA

#123
20210163403
2021-06-03

COMPOSITIONS AND METHODS FOR TREATING CANCER

#124
20210161873
2021-06-03

Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof

#125
20210138084
2021-05-13

Conjugates of active pharmaceutical ingredients

#126
20210100927
2021-04-08

Bioactive polymeric dressing for accelerated wound closure

#127
20210069126
2021-03-11

Intranasal Formulation of Epinephrine for the Treatment of Anaphylaxis

#128
20200399642
2020-12-24

METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING METASTATIC TUMORS

#129
20200383951
2020-12-10

METHODS FOR TREATING DEPENDENCE

#130
20200345700
2020-11-05

LSD1 inhibitor and preparation method and application thereof

#131
20200338147
2020-10-29

Compositions and methods of treatment of Ehlers-Danlos syndromes

#132
20200331847
2020-10-22

Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

#133
20200281873
2020-09-10

Adamantane or Bicyclic Monoterpenoid Derivatives for Use in the Treatment of Leishmaniasis

#134
20200268729
2020-08-27

CXCR4 antagonists with amino acid skeleton, preparation therefor and biomedical use thereof

#135
20200253931
2020-08-13

Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders

#136
20200246310
2020-08-06

Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders

#137
20200222505
2020-07-16

METHODS OF DELAYING AND PREVENTING ACUTE MYELOID LEUKEMIA RELAPSE

#138
20200197343
2020-06-25

Compositions and methods for treatment of inflammation

#139
20200163951
2020-05-28

Composition and methods for the treatment of myopia

#140
20200157050
2020-05-21

KCNQ2-5 CHANNEL ACTIVATOR

#141
20200109142
2020-04-09

5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases

#142
20200108043
2020-04-09

COMPOUNDS AND COMPOSITIONS FOR EXTENDING LIFESPAN OF A SUBJECT

#143
20200055948
2020-02-20

CELLS EXPRESSING A BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR

#144
20190382827
2019-12-19

USE OF MICROBIAL METABOLITES FOR TREATING DISEASES

#145
20190381009
2019-12-19

DBH inhibitors for treating or preventing memory loss

#146
20190367631
2019-12-05

Anti-MSR1 antibodies and methods of use thereof

#147
20190359727
2019-11-28

Combination therapies for treatment of BCMA-related cancers and autoimmune disorders

#148
20190358152
2019-11-28

Aqueous ophthalmic solutions of phentolamine and medical uses thereof

#149
20190343804
2019-11-14

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#150
20190328710
2019-10-31

SYNERGISTIC COMPOSITION FOR INHIBITING ADVANCED GLYCATION END PRODUCT CROSSLINKING

#151
20190290722
2019-09-26

TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY

#152
20190269673
2019-09-05

Uses of dopamine beta-hydroxylase (DBH) inhibitors and serotonin receptor (5-HT) antagonists for the treatment of cancer

#153
20190254963
2019-08-22

Aqueous ophthalmic solutions of phentolamine and medical uses thereof

#154
20190241545
2019-08-08

1,3-Dihydroimidazole-2-Thione Derivatives for Use in the Treatment of Pulmonary Arterial Hypertension and Lung Injury

#155
20190241506
2019-08-08

Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

#156
20190194135
2019-06-27

Modulators of the integrated stress pathway

#157
20190194124
2019-06-27

Compositions and methods for treating cancer

#158
20190175557
2019-06-13

COMPOUNDS USEFUL FOR DECREASING INTERFERON LEVEL

#159
20190175549
2019-06-13

CXCR4 receptor-binding compounds useful for increasing interferon level

#160
20190175477
2019-06-13

Medicament

#161
20190160005
2019-05-30

Method of Preparing Solid Dispersions of Active Pharmaceutical Ingredients

#162
20190091168
2019-03-28

FORMULATION FOR ENHANCED TRANSDERMAL ABSORPTION OF DRUG

#163
20190055201
2019-02-21

Methods for producing optically active valeric acid derivatives

#164
20190022037
2019-01-24

Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies

#165
20190000972
2019-01-03

Method for binding active agents to activated autologous blood nosodes and device for performing said method

#166
20180369201
2018-12-27

DBH inhibitors for treating memory loss

#167
20180353479
2018-12-13

Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function

#168
20180346422
2018-12-06

KCNQ2-5 channel activator

#169
20180318260
2018-11-08

COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS

#170
20180297939
2018-10-18

Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

#171
20180280353
2018-10-04

METHODS FOR RESTORATION OF HISTAMINE BALANCE

#172
20180250255
2018-09-06

Compositions and methods for treatment of inflammation

#173
20180228772
2018-08-16

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#174
20180221342
2018-08-09

Hepatitis C virus inhibitors

#175
20180221340
2018-08-09

Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance

#176
20180221274
2018-08-09

Aqueous ophthalmic solutions of phentolamine and medical uses thereof

#177
20180177749
2018-06-28

USE OF CYP EXPRESSION TO DIRECT THERAPEUTIC INTERVENTION IN CANCER

#178
20180148770
2018-05-31

USE OF MICROBIAL METABOLITES FOR TREATING DISEASES

#179
20180147184
2018-05-31

Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of diminished tissue function

#180
20180127353
2018-05-10

Compounds for use as therapeutic agents affecting P53 expression and/or activity

#181
20180085306
2018-03-29

Therapeutic compounds and formulations for intranasal delivery

#182
20180064810
2018-03-08

USE OF RANK/RANKL ANTAGONISTS FOR TREATING NEUROMUSCULAR DISORDERS, GENETIC MYOPATHIES AND/OR NON GENETIC MYOPATHIES AND/OR FOR REGULATING SKELETAL AND CARDIAC MUSCLE DISUSE, DISEASES AND AGING

#183
20180064660
2018-03-08

AMINO ALCOHOL DERIVATIVES FOR THE TREATMENT OF DEMYELINATING PERIPHERAL NEUROPATHIES

#184
20180044282
2018-02-15

ALPHA-CINNAMIDE COMPOUNDS AND COMPOSITIONS AS HDAC8 INHIBITORS

#185
20180029993
2018-02-01

Methods for producing optically active valeric acid derivatives

#186
20170369477
2017-12-28

1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

#187
20170368000
2017-12-28

Intranasal formulation of epinephrine for the treatment of anaphylaxis

#188
20170340612
2017-11-30

TREATMENT FOR CUTANEOUS T CELL LYMPHOMA

#189
20170334855
2017-11-23

KCNQ2-5 channel activator

#190
20170326110
2017-11-16

Solid pharmaceutical composition comprising amlodipine and losartan

#191
20170319590
2017-11-09

Pharmaceutical formulations of xanthine or xanthine derivatives, and their use

#192
20170304326
2017-10-26

Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to damage

#193
20170291878
2017-10-12

Methods for producing optically active valeric acid derivatives

#194
20170266163
2017-09-21

Methods for restoration of histamine balance

#195
20170239259
2017-08-24

ARYLOXY PHENOXY ACRYLIC COMPOUND HAVING HIF-1 INHIBITION ACTIVITY, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT

#196
20170209539
2017-07-27

Therapeutic Treatment For Metabolic Syndrome, Type 2 Diabetes, Obesity, Or Prediabetes

#197
20170209532
2017-07-27

Two part formulation system for ophthalmic delivery

#198
20170143674
2017-05-25

Use of Glutaryl Histamine for the Treatment of Respiratory Tract Diseases

#199
20170135986
2017-05-18

Stabilized multi-functional antioxidant compounds and methods of use

#200
20170119737
2017-05-04

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#201
20170112564
2017-04-27

METHODS AND MATERIALS FOR TREATING HYPERTENSION

#202
20170087164
2017-03-30

METHOD AND COMPOSITION FOR ENHANCEMENT OF MALE ERECTILE FUNCTION

#203
20170044117
2017-02-16

Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation

#204
20170000853
2017-01-05

WOUND HEALING COMPOSITION

#205
20160354393
2016-12-08

Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to damage

#206
20160354345
2016-12-08

Method for preventing or treating diseases associated with a reduced density of interferon receptors

#207
20160324844
2016-11-10

Method of inhibiting the glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids

#208
20160317552
2016-11-03

PHARMACEUTICAL FORMULATIONS FOR TREATING MALE SEXUAL DYSFUNCTIONS

#209
20160264518
2016-09-15

Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

#210
20160235711
2016-08-18

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#211
20160235666
2016-08-18

Two part formulation system for ophthalmic delivery

#212
20160220489
2016-08-04

Intranasal Formulation for the Treatment of Cardiopulmonary Resuscitation (CPR), Cardiac Life Support (CLS), Anaphylaxis and/or Anaphylactoid Reactions

#213
20160175286
2016-06-23

Selective AT2 receptor agonists for use in treatment of cachexia

#214
20160175272
2016-06-23

Compositions and methods for treatment of inflammation

#215
20160166519
2016-06-16

Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies

#216
20160151308
2016-06-02

Cycloalkyl-diamines for neurodegenerative disorders

#217
20160120924
2016-05-05

Methods and compositions for treating and preventing signs or symptoms of eye disease

#218
20160120890
2016-05-05

Compositions and methods for treating or preventing metabolic syndrome disorders

#219
20160101091
2016-04-14

Alkylamine derivative

#220
20160082073
2016-03-24

Pharmaceutical composition for treating a microbial infection

#221
20160051515
2016-02-25

Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance

#222
20160045502
2016-02-18

Therapeutic benefit of suboptimally administered chemical compounds

#223
20160024091
2016-01-28

Inhibitors of the renal outer medullary potassium channel

#224
20160015630
2016-01-21

SPRAYABLE OXYGENATED SALINE COMPOSITION AND METHOD FOR TREATING NASAL CONGESTION, ALLERGY, DRYNESS, EYE IRRITATION, THROAT IRRITATION, WOUNDS, AND SKIN AS APPLIED TO HUMAN TISSUES

#225
20160008340
2016-01-14

Pharmaceutical composition including migratory factor for guiding pluripotent stem cells to injury

#226
20160000777
2016-01-07

METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS

#227
20150342909
2015-12-03

Therapeutic compounds and methods

#228
20150299172
2015-10-22

1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

#229
20150218107
2015-08-06

Aggrecanase inhibitors

#230
20150209516
2015-07-30

System and method for treating erectile dysfunction

#231
20150209339
2015-07-30

Hetero-Substituted Acetanilide Derivatives As Analgesic Agents

#232
20150209331
2015-07-30

Histamine balance restoration methods

#233
20150209330
2015-07-30

Method and agent for the treatment and prophylaxis of diseases caused by (+)RNA-containing viruses

#234
20150191439
2015-07-09

Inhibitors targeting drug-resistant influenza A

#235
20150191435
2015-07-09

Dual-acting imidazole antihypertensive agents

#236
20150190377
2015-07-09

NEURONAL REGENERATION

#237
20150150848
2015-06-04

METHOD FOR OPTIMIZING VISION

#238
20150148395
2015-05-28

Amide derivatives of N-urea substituted amino acids as formyl peptide receptor like-1 (FPRL-1) receptor modulators

#239
20150126501
2015-05-07

Fused ring compound for use as mineralocorticoid receptor antagonist

#240
20150099019
2015-04-09

Methods and compositions for treating and preventing signs or symptoms of eye disease

#241
20150073027
2015-03-12

Preservation of Ergothioneine

#242
20150065543
2015-03-05

Dual-acting antihypertensive agents

#243
20150064135
2015-03-05

Agent for the treatment of viral hepatitis C

#244
20150051444
2015-02-19

DRUG DELIVERY SYSTEM FOR TREATING ERECTILE DYSFUNCTION

#245
20150038541
2015-02-05

COMPOSITION AND METHODS FOR CELL MODULATION

#246
20150031705
2015-01-29

OPHTHALMIC FORMULATIONS INCLUDING SELECTIVE ALPHA 1 ANTAGONISTS

#247
20150017151
2015-01-15

Pharmaceutical formulations of xanthine or xanthine derivatives, and their use

#248
20150005356
2015-01-01

Intranasal formulation of epinephrine for the treatment of anaphylaxis

#249
20140364379
2014-12-11

TWO PART FORMULATION SYSTEM FOR OPHTHALMIC DELIVERY

#250
20140309268
2014-10-16

Methods for restoration of histamine balance

#251
20140303222
2014-10-09

Dual-acting imidazole antihypertensive agents

#252
20140302023
2014-10-09

Use of RANK/RANKL antagonists for treating muscular dystrophy

#253
20140294808
2014-10-02

Treating cancer with HSP90 inhibitory compounds

#254
20140287988
2014-09-25

MACROGOL 15 HYDROXYSTEARATE FORMULATIONS

#255
20140271854
2014-09-18

Opioid receptor modulator dosage formulations

#256
20140221446
2014-08-07

Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance

#257
20140221445
2014-08-07

Aqueous ophthalmic solutions of phentolamine and medical uses thereof

#258
20140206690
2014-07-24

Compounds for use as therapeutic agents affecting p53 expression and/or activity

#259
20140178349
2014-06-26

Cycloalkyl-substituted imidazole derivative

#260
20140128329
2014-05-08

Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers

#261
20140121256
2014-05-01

METHOD OF TREATING MUSCULAR WEAKNESS COMPRISING ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE AMOUNT OF HISTAMINE AND/OR SEROTONIN

#262
20140107124
2014-04-17

Prostamides for the treatment of glaucoma and related diseases

#263
20140099336
2014-04-10

Methods for treating dependence

#264
20140024835
2014-01-23

Intermediates for preparing dual-acting benzyl triazole antihypertensive agents having angiotensin II type I receptor antagonist activity and neprilysin-inhibition activity

#265
20140005244
2014-01-02

Family of polyamine arylethylamide compounds, and their cosmetic or dermocosmetic use

#266
20140004082
2014-01-02

Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins

#267
20130345149
2013-12-26

SILICONE-BASED OPHTHALMIC FORMULATIONS

#268
20130303566
2013-11-14

METHOD FOR TREATING MACULAR DEGENERATION

#269
20130303564
2013-11-14

METHOD FOR TREATING A NEURODEGENERATIVE DISORDER

#270
20130289029
2013-10-31

Fused ring compound for use as mineralocorticoid receptor antagonist

#271
20130274303
2013-10-17

METHODS AND COMPOSITIONS FOR TREATMENT OF DRUG ADDICTION

#272
20130266588
2013-10-10

Agents, compositions, and methods for treating pruritus and related skin conditions

#273
20130243886
2013-09-19

Pharmaceutical composition and method of treating a microbial infection with sulcotidil

#274
20130230501
2013-09-05

Cycloalkyl-Substituted Imidazole Derivative

#275
20130190355
2013-07-25

Dual inhibitors of farnesyltransferase and geranylgeranyltransferase I

#276
20130184283
2013-07-18

Method for treating psoriasis

#277
20130096162
2013-04-18

Dual-acting benzyl triazole antihypertensive agents having angiotensin II type receptor antagonist activity and neprilysin-inhibition activity

#278
20130072491
2013-03-21

Prophylactic or therapeutic agent for diabetes or obesity

#279
20130053335
2013-02-28

Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine

#280
20130045203
2013-02-21

Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP

#281
20130029919
2013-01-31

TWO PART FORMULATION SYSTEM FOR OPTHALMIC DELIVERY

#282
20130022687
2013-01-24

TOPICAL TRANSDERMAL METHOD FOR DELIVERING NUTRIENTS THROUGH THE SKIN FOR EXPEDITED WOUND HEALING

#283
20130022587
2013-01-24

Cycloalkyl-substituted imidazole derivative

#284
20130005665
2013-01-03

MACROGOL 15 HYDROXYSTEARATE FORMULATIONS

#285
20120309744
2012-12-06

DOSING REGIMENS AND METHODS FOR TREATING OR PREVENTING HEPATOCELLULAR CARCINOMA

#286
20120277423
2012-11-01

Inhibitor of protein crosslinking and use of the same

#287
20120264752
2012-10-18

Dual-acting antihypertensive agents

#288
20120225952
2012-09-06

NON-AQUEOUS SILICONE-BASED OPHTHALMIC FORMULATIONS

#289
20120225827
2012-09-06

SILICONE-BASED OPHTHALMIC FORMULATIONS

#290
20120178784
2012-07-12

Use of inhibitors of the renin-angiotensin system

#291
20120165381
2012-06-28

Dual-acting imidazole antihypertensive agents

#292
20120134985
2012-05-31

METHODS FOR MODULATING METABOLIC AND CIRCADIAN RHYTHMS

#293
20120129781
2012-05-24

COMPOSITION COMPRISING ALPHA-LIPOIC ACID AND CARNOSINE FOR TREATING THE PHANTOM LIMB SYNDROME

#294
20120108632
2012-05-03

PRENYLTRANSFERASE INHIBITORS FOR OCULAR HYPERTENSION CONTROL AND THE TREATMENT OF GLAUCOMA

#295
20120082656
2012-04-05

COMPOSITION COMPRISING THE PURIFIED EXTRACT OF BEE VENOM FOR PREVENTING AND TREATING DEGENERATIVE BRAIN DISEASE

#296
20120039844
2012-02-16

COMPOSITION AND USE OF N-ALPHA-METHYLHISTAMINE DIHYDROCHLORIDE FOR THE REDUCTION OF OXYGEN RADICAL FORMATION

#297
20120010157
2012-01-12

Method of stimulating the motility of the gastrointestinal system using ipamorelin

#298
20110288040
2011-11-24

Aryl- or heteroaryl-sulfonyl compounds as acid secretion inhibitors

#299
20110281925
2011-11-17

Dual-acting antihypertensive agents

#300
20110263498
2011-10-27

Method and composition for enhancement of male erectile function